Reverse the Resistance to PARP Inhibitors

被引:67
|
作者
Kim, Yevgeniy [1 ]
Kim, Aleksei [1 ]
Sharip, Ainur [1 ]
Sharip, Aigul [1 ]
Jiang, Juhong [2 ]
Yang, Qing [1 ]
Xie, Yingqiu [1 ]
机构
[1] Nazarbayev Univ, Sch Sci & Technol, Dept Biol, 53 Kabanbay Batyr Ave, Astana 010000, Kazakhstan
[2] Guangzhou Med Univ, Affiliated Hosp 1, Dept Pathol, Guangzhou, Guangdong, Peoples R China
来源
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES | 2017年 / 13卷 / 02期
基金
中国国家自然科学基金;
关键词
PARP; PARP inhibitor; drug resistance; DNA repair; STRAND-BREAK REPAIR; SHOCK-PROTEIN; 90; HOMOLOGOUS RECOMBINATION; DNA-REPAIR; SECONDARY MUTATIONS; SYNTHETIC LETHALITY; MILD HYPERTHERMIA; TUMOR SUPPRESSION; CANCER-CELLS; BRCA1;
D O I
10.7150/ijbs.17240
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
One of the DNA repair machineries is activated by Poly ( ADP- ribose) Polymerase ( PARP) enzyme. Particularly, this enzyme is involved in repair of damages to single- strand DNA, thus decreasing the chances of generating double- strand breaks in the genome. Therefore, the concept to block PARP enzymes by PARP inhibitor ( PARPi) was appreciated in cancer treatment. PARPi has been designed and tested for many years and became a potential supplement for the conventional chemotherapy. However, increasing evidence indicates the appearance of the resistance to this treatment. Specifically, cancer cells may acquire new mutations or events that overcome the positive effect of these drugs. This paper describes several molecular mechanisms of PARPi resistance which were reported most recently, and summarizes some strategies to reverse this type of drug resistance.
引用
收藏
页码:198 / 208
页数:11
相关论文
共 50 条
  • [21] Insights into the Possible Molecular Mechanisms of Resistance to PARP Inhibitors
    Piombino, Claudia
    Cortesi, Laura
    CANCERS, 2022, 14 (11)
  • [22] Understanding and overcoming resistance to PARP inhibitors in cancer therapy
    Dias, Mariana Paes
    Moser, Sarah C.
    Ganesan, Shridar
    Jonkers, Jos
    NATURE REVIEWS CLINICAL ONCOLOGY, 2021, 18 (12) : 773 - 791
  • [23] New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer
    Han, Ye
    Yu, Xiaopeng
    Li, Shuqiang
    Tian, Ye
    Liu, Caigang
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [24] PARP Inhibitors Resistance: Mechanisms and Perspectives
    Giudice, Elena
    Gentile, Marica
    Salutari, Vanda
    Ricci, Caterina
    Musacchio, Lucia
    Carbone, Maria Vittoria
    Ghizzoni, Viola
    Camarda, Floriana
    Tronconi, Francesca
    Nero, Camilla
    Ciccarone, Francesca
    Scambia, Giovanni
    Lorusso, Domenica
    CANCERS, 2022, 14 (06)
  • [25] With Our Powers Combined Exploring PARP Inhibitors and Immunotherapy
    Kasherman, Lawrence
    Karakasis, Katherine
    Oza, Amit M.
    CANCER JOURNAL, 2021, 27 (06) : 511 - 520
  • [26] The potential of PARP inhibitors in targeted cancer therapy and immunotherapy
    Hunia, Jaromir
    Gawalski, Karol
    Szredzka, Aleksandra
    Suskiewicz, Marcin J.
    Nowis, Dominika
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2022, 9
  • [27] PARP inhibitors for anticancer therapy
    Curtin, Nicola
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2014, 42 : 82 - 88
  • [28] PARP Inhibitors in Pancreatic Cancer
    Brown, Timothy J.
    Reiss, Kim A.
    CANCER JOURNAL, 2021, 27 (06) : 465 - 475
  • [29] EGFR and c-MET Cooperate to Enhance Resistance to PARP Inhibitors in Hepatocellular Carcinoma
    Dong, Qiongzhu
    Du, Yi
    Li, Hui
    Liu, Chunxiao
    Wei, Yongkun
    Chen, Mei-Kuang
    Zhao, Xixi
    Chu, Yu-Yi
    Qiu, Yufan
    Qin, Lunxiu
    Yamaguchi, Hirohito
    Hung, Mien-Chie
    CANCER RESEARCH, 2019, 79 (04) : 819 - 829
  • [30] PARP Inhibitors and Proteins Interacting with SLX4
    Jordheim, Lars Petter
    CANCERS, 2023, 15 (03)